Related Experiment Video

Updated: Apr 18, 2026

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials
06:18

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials

Published on: March 3, 2023

2.0K

Local antibiotic delivery systems in diabetic foot osteomyelitis: time for one step beyond?

Periklis Panagopoulos1, Georgios Drosos2, Efstratios Maltezos3

  • 1Unit of Infectious Diseases, 2nd Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis, Greece.

The International Journal of Lower Extremity Wounds
|January 22, 2015
PubMed

Insights

Diabetic foot osteomyelitis is a severe infection. New methods using carriers for local antibiotic delivery show promise for treating this condition, with clinical trials pending to confirm their role.

Area of Science:

  • Orthopedics
  • Infectious Diseases
  • Podiatry

Background:

  • Osteomyelitis in diabetic patients presents a significant clinical challenge.
  • Diabetic foot infections require effective treatment strategies to prevent complications.

Purpose of the Study:

  • To explore the use of local antimicrobial delivery carriers for diabetic foot osteomyelitis.
  • To evaluate the potential of achieving high local antibiotic concentrations.

Main Methods:

  • Review of current management strategies for diabetic foot osteomyelitis.
  • Discussion of emerging approaches involving local drug delivery systems.

Main Results:

  • Local delivery carriers are being investigated for enhanced antibiotic concentrations at the infection site.
  • This approach aims to improve treatment outcomes for diabetic foot osteomyelitis.

Conclusions:

  • Further randomized clinical trials are necessary to establish the efficacy and optimal integration of local antimicrobial delivery.
  • This innovative strategy may offer a new therapeutic avenue for managing diabetic foot osteomyelitis.
Keywords:
antibioticsdelivery systemsdiabetes mellitusdiabetic footinfectionsosteomyelitistreatment

More Related Videos

Doxycycline Loaded Collagen-Chitosan Composite Scaffold for the Accelerated Healing of Diabetic Wounds10:49

Doxycycline Loaded Collagen-Chitosan Composite Scaffold for the Accelerated Healing of Diabetic Wounds

Published on: August 21, 2021

5.1K
Come to the Light Side: In Vivo Monitoring of Pseudomonas aeruginosa Biofilm Infections in Chronic Wounds in a Diabetic Hairless Murine Model09:15

Come to the Light Side: In Vivo Monitoring of Pseudomonas aeruginosa Biofilm Infections in Chronic Wounds in a Diabetic Hairless Murine Model

Published on: October 10, 2017

14.3K

Related Concept Videos

Diabetic Foot Ulcer01:31

Diabetic Foot Ulcer

Definition A diabetic foot ulcer (DFU) is a chronic, non-healing wound that develops in individuals with diabetes. It typically occurs on pressure-bearing areas such as the heel, metatarsal heads, or hallux, and carries a high risk of infection and amputation.Pathophysiology • The development of DFUs can be explained by four interconnected mechanisms: neuropathy, ischemia, infection, and impaired wound healing. • Neuropathy is the most common factor. Sensory...
1
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
268
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices01:28

Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices

Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...
176
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
155
Modified-Release Drug Delivery Systems: Stimuli-Activated01:30

Modified-Release Drug Delivery Systems: Stimuli-Activated

Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
146
Drug Delivery Systems: Different Types01:27

Drug Delivery Systems: Different Types

Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
355